Myeloid-derived suppressor cells suppress graft-versus- host disease without abrogating graft-versus-leukemia effects after allogeneic hematopoietic stem cell transplantation.
Cancer research. Forthcoming.
SV food mediated immune modulation of the tumor microenvironment and antitumor mechanism.
Cancer research. Forthcoming.
Novel platinum therapeutics induce rapid cancer cell death through triggering intracellular ROS storm.
Biomaterials.
2024 Sep 11;314:122835. doi: 10.1016/j.biomaterials.2024.122835. [Epub ahead of print] PubMed PMID:
39276409; NIHMSID:NIHMS2024348.
LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy.
Cancer Res.
2023 Dec 15;83(24):4047-4062. doi: 10.1158/0008-5472.CAN-22-2483. PubMed PMID:
38098451; NIHMSID:NIHMS2005375.
Dedifferentiation-mediated stem cell niche maintenance in early-stage ductal carcinoma in situ progression: insights from a multiscale modeling study.
Cell Death Dis.
2022 May 21;13(5):485. doi: 10.1038/s41419-022-04939-x. PubMed PMID:
35597788; PubMed Central PMCID:
PMC9124196.
Identification of an Aptamer With Binding Specificity to Tumor-Homing Myeloid-Derived Suppressor Cells.
Front Pharmacol.
2021;12:752934. doi: 10.3389/fphar.2021.752934. eCollection 2021. PubMed PMID:
35126104; PubMed Central PMCID:
PMC8814529.
The Sympathetic Nervous System Modulates Cancer Vaccine Activity through Monocyte-Derived Cells.
J Immunol.
2021 Dec 15;207(12):3131-3140. doi: 10.4049/jimmunol.2100719. Epub 2021 Nov 12. PubMed PMID:
34772699; PubMed Central PMCID:
PMC9583274.
Nutrient supplements from selected botanicals mediated immune modulation of the tumor microenvironment and antitumor mechanism.
Cancer Immunol Immunother.
2021 Dec;70(12):3435-3449. doi: 10.1007/s00262-021-02927-2. Epub 2021 Apr 20. PubMed PMID:
33877384; PubMed Central PMCID:
PMC10991198.
Early prediction of clinical response to checkpoint inhibitor therapy in human solid tumors through mathematical modeling.
Elife.
2021 Nov 9;10. doi: 10.7554/eLife.70130. PubMed PMID:
34749885; PubMed Central PMCID:
PMC8629426.
Potentiating Antitumor Efficacy Through Radiation and Sustained Intratumoral Delivery of Anti-CD40 and Anti-PDL1.
Int J Radiat Oncol Biol Phys.
2021 Jun 1;110(2):492-506. doi: 10.1016/j.ijrobp.2020.07.2326. Epub 2020 Aug 5. PubMed PMID:
32768562; PubMed Central PMCID:
PMC8547413.
Synergistic Activation of Antitumor Immunity by a Particulate Therapeutic Vaccine.
Adv Sci (Weinh).
2021 Jun;8(12):2100166. doi: 10.1002/advs.202100166. eCollection 2021 Jun. PubMed PMID:
34194942; PubMed Central PMCID:
PMC8224417.
Myeloid-derived suppressor cells as cellular immunotherapy in transplantation and autoimmune diseases.
Cell Immunol.
2021 Apr;362:104300. doi: 10.1016/j.cellimm.2021.104300. Epub 2021 Feb 4. Review. PubMed PMID:
33582607; PubMed Central PMCID:
PMC8019491.
Analyzing One Cell at a TIME: Analysis of Myeloid Cell Contributions in the Tumor Immune Microenvironment.
Front Immunol.
2020;11:1842. doi: 10.3389/fimmu.2020.01842. eCollection 2020. Review. PubMed PMID:
32983100; PubMed Central PMCID:
PMC7492293.
A modeling platform for the lymphatic system.
J Theor Biol.
2020 May 21;493:110193. doi: 10.1016/j.jtbi.2020.110193. Epub 2020 Feb 28. PubMed PMID:
32119968; PubMed Central PMCID:
PMC7297266.
Mathematical prediction of clinical outcomes in advanced cancer patients treated with checkpoint inhibitor immunotherapy.
Sci Adv.
2020 May;6(18):eaay6298. doi: 10.1126/sciadv.aay6298. eCollection 2020 May. PubMed PMID:
32426472; PubMed Central PMCID:
PMC7190324.
Systematic comparison of methods for determining the in vivo biodistribution of porous nanostructured injectable inorganic particles.
Acta Biomater.
2019 Oct 1;97:501-512. doi: 10.1016/j.actbio.2019.08.002. Epub 2019 Aug 3. PubMed PMID:
31386927; PubMed Central PMCID:
PMC9646250.
The mechanistic study behind suppression of GVHD while retaining GVL activities by myeloid-derived suppressor cells.
Leukemia.
2019 Aug;33(8):2078-2089. doi: 10.1038/s41375-019-0394-z. Epub 2019 Feb 8. PubMed PMID:
30737483; PubMed Central PMCID:
PMC6687551.
Tracking Biodistribution of Myeloid-Derived Cells in Murine Models of Breast Cancer.
Genes (Basel).
2019 Apr 12;10(4). doi: 10.3390/genes10040297. PubMed PMID:
31013756; PubMed Central PMCID:
PMC6523772.
Investigation of parameters that determine Nano-DC vaccine transport.
Biomed Microdevices.
2019 Apr 4;21(2):39. doi: 10.1007/s10544-019-0397-6. PubMed PMID:
30949852; PubMed Central PMCID:
PMC6686196.
Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity.
J Clin Invest.
2018 Dec 3;128(12):5647-5662. doi: 10.1172/JCI97570. Epub 2018 Oct 22. PubMed PMID:
30352428; PubMed Central PMCID:
PMC6264729.
Sensitizing non-small cell lung cancer to BCL-xL-targeted apoptosis.
Cell Death Dis.
2018 Sep 24;9(10):986. doi: 10.1038/s41419-018-1040-9. PubMed PMID:
30250075; PubMed Central PMCID:
PMC6155218.
Glatiramer Acetate Enhances Myeloid-Derived Suppressor Cell Function via Recognition of Paired Ig-like Receptor B.
J Immunol.
2018 Sep 15;201(6):1727-1734. doi: 10.4049/jimmunol.1701450. Epub 2018 Aug 1. PubMed PMID:
30068593; PubMed Central PMCID:
PMC6379207.
Leukocyte immunoglobulin-like receptors in human diseases: an overview of their distribution, function, and potential application for immunotherapies.
J Leukoc Biol.
2017 Aug;102(2):351-360. doi: 10.1189/jlb.5MR1216-534R. Epub 2017 Mar 28. Review. PubMed PMID:
28351852; PubMed Central PMCID:
PMC5505746.
LILRB receptor-mediated regulation of myeloid cell maturation and function.
Cancer Immunol Immunother.
2017 Aug;66(8):1079-1087. doi: 10.1007/s00262-017-2023-x. Epub 2017 Jun 21. Review. PubMed PMID:
28638976; PubMed Central PMCID:
PMC5591173.
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards.
Nat Commun.
2016 Jul 6;7:12150. doi: 10.1038/ncomms12150. Review. PubMed PMID:
27381735; PubMed Central PMCID:
PMC4935811.
5-Fluorouracil targets thymidylate synthase in the selective suppression of TH17 cell differentiation.
Oncotarget.
2016 Apr 12;7(15):19312-26. doi: 10.18632/oncotarget.8344. PubMed PMID:
27027355; PubMed Central PMCID:
PMC4991385.
Myeloid-Derived Suppressor Cells as an Immune Parameter in Patients with Concurrent Sunitinib and Stereotactic Body Radiotherapy.
Clin Cancer Res.
2015 Sep 15;21(18):4073-4085. doi: 10.1158/1078-0432.CCR-14-2742. Epub 2015 Apr 28. PubMed PMID:
25922428; PubMed Central PMCID:
PMC4720266.
DC-SIGN(+) Macrophages Control the Induction of Transplantation Tolerance.
Immunity.
2015 Jun 16;42(6):1143-58. doi: 10.1016/j.immuni.2015.05.009. Epub 2015 Jun 9. PubMed PMID:
26070485; PubMed Central PMCID:
PMC4690204.
A novel role of microglial NADPH oxidase in mediating extra-synaptic function of norepinephrine in regulating brain immune homeostasis.
Glia.
2015 Jun;63(6):1057-72. doi: 10.1002/glia.22801. Epub 2015 Mar 4. PubMed PMID:
25740080; PubMed Central PMCID:
PMC4405498.
Immunizations with hepatitis B viral antigens and a TLR7/8 agonist adjuvant induce antigen-specific immune responses in HBV-transgenic mice.
Int J Infect Dis.
2014 Dec;29:31-6. doi: 10.1016/j.ijid.2014.07.015. Epub 2014 Oct 23. PubMed PMID:
25449231; PubMed Central PMCID:
PMC4397646.
Low-density lipoprotein electronegativity is a novel cardiometabolic risk factor.
PLoS One.
2014;9(9):e107340. doi: 10.1371/journal.pone.0107340. eCollection 2014. PubMed PMID:
25203525; PubMed Central PMCID:
PMC4159324.
Downregulation of CD40 expression contributes to the accumulation of myeloid-derived suppressor cells in gastric tumors.
Oncol Lett.
2014 Aug;8(2):775-780. doi: 10.3892/ol.2014.2174. Epub 2014 May 26. PubMed PMID:
25009656; PubMed Central PMCID:
PMC4081434.
Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases: final report of a prospective clinical trial.
Target Oncol.
2014 Jun;9(2):145-53. doi: 10.1007/s11523-013-0280-y. Epub 2013 May 10. PubMed PMID:
23660867; PubMed Central PMCID:
PMC4339281.
Immune cells: more than simple carriers for systemic delivery of oncolytic viruses.
Oncolytic Virother.
2014;3:83-91. doi: 10.2147/OV.S47143. PubMed PMID:
25767789; PubMed Central PMCID:
PMC4354653.
Myeloid-derived suppressor cells as a vehicle for tumor-specific oncolytic viral therapy.
Cancer Res.
2013 Aug 15;73(16):5003-15. doi: 10.1158/0008-5472.CAN-12-1597. Epub 2013 Mar 27. PubMed PMID:
23536556; PubMed Central PMCID:
PMC3745543.
Myeloid-derived suppressor cells as a Trojan horse: A cellular vehicle for the delivery of oncolytic viruses.
Oncoimmunology.
2013 Aug 1;2(8):e25083. doi: 10.4161/onci.25083. Epub 2013 May 28. PubMed PMID:
24083075; PubMed Central PMCID:
PMC3782526.
T cell–derived inducible nitric oxide synthase switches off Th17 cell differentiation.
J Exp Med.
2013 Jul 1;210(7):1447-62. doi: 10.1084/jem.20122494. PubMed PMID:
23797094; PubMed Central PMCID:
PMC3698516.
Polarization and reprogramming of myeloid-derived suppressor cells.
J Mol Cell Biol.
2013 Jun;5(3):207-9. doi: 10.1093/jmcb/mjt009. Epub 2013 Mar 25. PubMed PMID:
23532593; PubMed Central PMCID:
PMC3695657.
Lymphatic vasculature mediates macrophage reverse cholesterol transport in mice.
J Clin Invest.
2013 Apr;123(4):1571-9. doi: 10.1172/JCI63685. Epub 2013 Mar 25. PubMed PMID:
23524964; PubMed Central PMCID:
PMC3613904.
Myeloid-derived suppressor cells in transplantation and cancer.
Immunol Res.
2012 Dec;54(1-3):275-85. doi: 10.1007/s12026-012-8335-1. Review. PubMed PMID:
22535241; PubMed Central PMCID:
PMC4000733.
γ-H2AX kinetics as a novel approach to high content screening for small molecule radiosensitizers.
PLoS One.
2012;7(6):e38465. doi: 10.1371/journal.pone.0038465. Epub 2012 Jun 29. PubMed PMID:
22768044; PubMed Central PMCID:
PMC3387170.
Phase II trial of concurrent sunitinib and image-guided radiotherapy for oligometastases.
PLoS One.
2012;7(6):e36979. doi: 10.1371/journal.pone.0036979. Epub 2012 Jun 27. PubMed PMID:
22761653; PubMed Central PMCID:
PMC3384658.
Tumor-expressed inducible nitric oxide synthase controls induction of functional myeloid-derived suppressor cells through modulation of vascular endothelial growth factor release.
J Immunol.
2012 Jun 1;188(11):5365-76. doi: 10.4049/jimmunol.1103553. Epub 2012 Apr 23. PubMed PMID:
22529296; PubMed Central PMCID:
PMC3358566.
Inhibitory receptors bind ANGPTLs and support blood stem cells and leukaemia development.
Nature.
2012 May 30;485(7400):656-60. doi: 10.1038/nature11095. PubMed PMID:
22660330; PubMed Central PMCID:
PMC3367397.
R-Ras is required for murine dendritic cell maturation and CD4+ T-cell priming.
Blood.
2012 Feb 16;119(7):1693-701. doi: 10.1182/blood-2011-05-357319. Epub 2011 Dec 14. PubMed PMID:
22174156; PubMed Central PMCID:
PMC3286347.
Combined Inhibition of Epidermal Growth Factor Receptor and Cyclooxygenase-2 as a Novel Approach to Enhance Radiotherapy.
J Cell Sci Ther.
2011 Oct 13;1(2). doi: 10.4172/2157-7013.s1-002. PubMed PMID:
23483082; PubMed Central PMCID:
PMC3593102.
DNA vaccines delivered by human papillomavirus pseudovirions as a promising approach for generating antigen-specific CD8+ T cell immunity.
Cell Biosci.
2011 Jul 28;1:26. doi: 10.1186/2045-3701-1-26. PubMed PMID:
21798027; PubMed Central PMCID:
PMC3162874.
Paired immunoglobin-like receptor-B regulates the suppressive function and fate of myeloid-derived suppressor cells.
Immunity.
2011 Mar 25;34(3):385-95. doi: 10.1016/j.immuni.2011.02.004. Epub 2011 Mar 3. PubMed PMID:
21376641; PubMed Central PMCID:
PMC3064726.
A functional recombinant human 4-1BB ligand for immune costimulatory therapy of cancer.
J Immunother.
2011 Mar;34(2):175-82. doi: 10.1097/CJI.0b013e318206dac1. PubMed PMID:
21304403; PubMed Central PMCID:
PMC3066178.
Targeting immune suppressing myeloid-derived suppressor cells in oncology.
Crit Rev Oncol Hematol.
2011 Jan;77(1):12-9. doi: 10.1016/j.critrevonc.2010.02.004. Epub 2010 Mar 20. Review. PubMed PMID:
20304669; PubMed Central PMCID:
PMC2927714.
What would you like to do?